Compare CYCU & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYCU | INTS |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 11.4M |
| IPO Year | 2021 | 2021 |
| Metric | CYCU | INTS |
|---|---|---|
| Price | $3.81 | $4.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 7.5M | 35.1K |
| Earning Date | 06-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $17,771,485.00 | N/A |
| Revenue This Year | $8.92 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $0.22 |
| 52 Week High | $7.13 | $8.06 |
| Indicator | CYCU | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 86.39 | 47.20 |
| Support Level | $0.69 | $3.95 |
| Resistance Level | $4.46 | $5.00 |
| Average True Range (ATR) | 0.12 | 0.34 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 91.05 | 31.45 |
Cycurion Inc. provides information technology security solutions through its subsidiaries. The company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company has one reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.